Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Effect of L-Dopa Therapy on Urinary p-Tyramine Excretion and EEG Changes in Parkinson's Disease

Abstract

P-TYRAMINE is a normal constituent of human urine1–8, excreted in free and conjugated forms2,4,8. The level of excretion is quantitatively evaluated by separating the phenolicamine fraction (isolated by absorption onto a ‘Biorad AG50W-X2’ column1) overnight in isopropylether: methylethyl ketone : acetic acid : water 9 : 1 : 5 : 5 (v/v) on a Whatman No. 2 paper strip followed by conversion to the 1-nitroso-2-naphthol fluorophore and photodensitometric evaluation9. This procedure has shown that approximately 60% of Parkinson patients excrete more unconjugated urinary p-tyramine than does a control group4,8,10. Food precursors rich in p-tyramine were shown to increase the levels of conjugated p-tyramine and its principal acid metabolite p-hydroxyphenylacetic acid (both free and bound forms)4,8,11. These three metabolites increased so as to account almost stoichometrically for the ingested amine4. Sterilization of the intestinal tract with neomycin and succinyl sulphathiazole in a patient with Parkinson's disease caused a considerable increase in both free and bound forms of both amine and acid4. These findings suggest that a proportion of conjugated p-tyramine and total p-hydroxyphenylacetic acid arise from exogenous sources whereas most of the free urinary p-tyramine is endogenous8. This observation is confirmed in the work of several others5–7 although Perry et al.7 interpret their findings differently. A more convincing demonstration of the validity of our hypothesis followed from an assessment of the urinary free and bound p-tyramine and p-hydroxyphenylacetic acid excreted in urine after oral and intravenous administration of p-hydroxyphenyl(ethylamine-2-14C)-hydrochloride. In a control population only a tiny proportion of ingested p-tyramine, even when substantially supplemented with cold amine, is excreted in the urine in the free form (Table 1). After intravenous injection, however, a variable but significant amount of unconjugated amine is excreted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Kakimoto, Y., and Armstrong, M. D., J. Biol. Chem., 237, 208 (1962).

    CAS  PubMed  Google Scholar 

  2. Boulton, A. A., Pollitt, R. J., and Majer, J. R., Nature, 215, 132 (1967).

    Article  ADS  CAS  PubMed  Google Scholar 

  3. Smith, I., and Kellow, A. H., Nature, 221, 1261 (1969).

    Article  ADS  CAS  PubMed  Google Scholar 

  4. Boulton, A. A., Prog. Neurogenetics, 1, 437 (1967).

    Google Scholar 

  5. Asatoor, A. M., Clin. Chim. Acta, 22, 223 (1968).

    Article  CAS  PubMed  Google Scholar 

  6. DeQuattro, V. L., and Sjoerdsma, A., Clin. Chim. Acta, 16, 227 (1967).

    Article  CAS  PubMed  Google Scholar 

  7. Perry, T. L., Hestrin, M., MacDougall, L., and Hansen, S., Clin. Chim. Acta, 14, 116 (1966).

    Article  CAS  PubMed  Google Scholar 

  8. Boulton, A. A., Marjerrison, G. L., and Majer, J. R., Symp. Clin. Biol. Res. Schizophrenia, Leningard (September 1970 in the press).

    Google Scholar 

  9. Boulton, A. A., Meth. Biochem. Anal., 16, 327 (1968).

    CAS  Google Scholar 

  10. Marjerrison, G. L., Boulton, A. A., and Rajput, A., Intern. J. Clin. Pharmacol., 4, 263 (1971).

    CAS  Google Scholar 

  11. Boulton, A. A., in L-Dopa and Parkinsonism (edit. by Barbeau, A., and McDowell, F. H.) (F. A. Davis, Philadelphia, 1970).

    Google Scholar 

  12. Barbeau, A., Murphy, G. F., and Sourkes, T. L., Science, 133, 1706 (1961).

    Article  ADS  CAS  PubMed  Google Scholar 

  13. Horneykiewicz, O., Pharmacol. Rev., 18, 925 (1966).

    Google Scholar 

  14. Cotzias, G. C., in L-Dopa and Parkinsonism (edit. by Barbeau, A., and McDowell, F. H.) (F. A. Davis, Philadelphia, 1970).

    Google Scholar 

  15. Goldstein, L., Sugerman, A. A., Stolberg, H., Murphree, H. B., and Pfeiffer, C. C., EEG Clin. Neurophysiol., 19, 350 (1965).

    Article  CAS  Google Scholar 

  16. Marjerrison, G. L., Krause, A. E., and Keogh, R. P., EEG Clin. Neurophysiol., 24, 35 (1968).

    Article  CAS  Google Scholar 

  17. Yahr, M. D., Duvoisin, R. C., Schear, M. J., Barrett, R. E., and Hoehn, M. M., Arch. Neurol., 21, 343 (1969).

    Article  CAS  PubMed  Google Scholar 

  18. Christenson, J. G., Pairman, W., and Udenfriend, S., Arch. Biochem. Biophys., 141, 356 (1970).

    Article  CAS  PubMed  Google Scholar 

  19. Boulton, A. A., and Quan, Lillian, Canad. J. Biochem., 48, 1287 (1970).

    Article  CAS  Google Scholar 

  20. Sourkes, T. L., Nature, 229, 413 (1971).

    Article  ADS  CAS  PubMed  Google Scholar 

  21. Fellman, J. H., and Roth, E. S., Biochemistry., 10, 408 (1971).

    Article  CAS  PubMed  Google Scholar 

  22. Boulton, A. A., and Majer, J. R., Nature, 225, 658 (1970).

    Article  PubMed  Google Scholar 

  23. Majer, J. R., and Boulton, A. A., J. Chromatog., 48, 322 (1970).

    Article  Google Scholar 

  24. Boulton, A. A., and Majer, J. R., Methods in Neurochemistry, 1, (edit. by Rodnight, R., and Marks, N.) (Plenum, New York, in the press).

  25. Majer, J. R., and Boulton, A. A., Meth. Biochem. Anal., 49, 993 (1971).

    Google Scholar 

  26. Boulton, A. A., and Majer, J. R., Canad. J. Biochem. (in the press).

  27. Sandler, M., Karoum, F., Ruthven, C. R. J., and Calne, D. B., Science, 166, 1417 (1969).

    Article  ADS  CAS  PubMed  Google Scholar 

  28. Sandler, M., Goodwin, B. L., Ruthven, C. R. J., and Calne, D. B., Nature, 229, 414 (1971).

    Article  ADS  CAS  PubMed  Google Scholar 

  29. Udenfriend, S., in Fluorescence Assay in Biology and Medicine, 164 (Academic Press, New York, 1962).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

BOULTON, A., MARJERRISON, G. Effect of L-Dopa Therapy on Urinary p-Tyramine Excretion and EEG Changes in Parkinson's Disease. Nature 236, 76–78 (1972). https://doi.org/10.1038/236076a0

Download citation

  • Received:

  • Revised:

  • Issue date:

  • DOI: https://doi.org/10.1038/236076a0

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing